EXPLAINER: Will mRNA Vaccines Cure Cancer? Artwork

Health Longevity Secrets

The health advice you're getting isn't working. Want to know what the experts actually do for themselves?

Health Longevity Secrets reveals the real science behind longevity, metabolic health, fasting, and disease reversal—the protocols that researchers and physicians use in their own lives, not just what they tell patients.

Robert Lufkin MD is a medical school professor, practicing physician, and New York Times bestselling author. After reversing his own chronic disease through lifestyle medicine, he's on a mission to share what actually works.

Each episode features in-depth interviews with world-class scientists, doctors, and biohackers who share their personal health strategies—no sponsored talking points, just real answers.

Your health transformation starts here.

All Episodes

Health Longevity Secrets

EXPLAINER: Will mRNA Vaccines Cure Cancer?

September 08, 2026 • Robert Lufkin MD

0:00 | 8:57

For the first time in history, a personalized mRNA cancer vaccine has passed a Phase 3 clinical trial. Robert Lufkin MD breaks down the Moderna/Merck melanoma result, how a vaccine custom-built from your own tumor actually works, the 49% drop in recurrence risk behind the headlines — and the honest answer to whether mRNA vaccines will cure cancer.

In this episode of Health Longevity Secrets, Robert Lufkin MD explains the science of personalized mRNA cancer vaccines: neoantigens, the AI-designed "most wanted poster" for your immune system, the five-year KEYNOTE-942 data, the stunning pancreatic cancer signal from Memorial Sloan Kettering, the BioNTech colorectal trial shutdown that reminds us why we run trials — and what still sits upstream of it all: your metabolic health.

Chapters:

00:00 — Introduction: A Cancer Vaccine Makes History
00:43 — What Just Happened: Moderna/Merck Phase 3 Melanoma Trial
01:44 — A Vaccine Made From Your Own Tumor: How It Works
02:31 — Neoantigens: A "Most Wanted Poster" for Your T-Cells
03:17 — The Numbers Behind the Hype: 49% Lower Recurrence at 5 Years
03:53 — Pancreatic Cancer Vaccine: The Sloan Kettering Survival Signal
04:44 — So Will mRNA Vaccines Cure Cancer? The Honest Answer
05:40 — The Platform Play: Lung, Kidney & Prostate Cancer Trials
06:09 — The Honest Caveats: Press Releases vs Peer Review
06:45 — The Colorectal Trial Shutdown: A Reality Check
07:57 — The Takeaway: Metabolic Health Still Sits Upstream

Key takeaways:

Intismeran autogene + Keytruda is the first mRNA cancer vaccine to succeed in a Phase 3 trial — FDA approval possibly by early 2027.
These are NOT prevention shots — each dose is custom-built from one patient's tumor mutations to hunt residual cancer cells after surgery.
Five-year Phase 2b data (KEYNOTE-942): 49% lower risk of recurrence or death, and 62% lower risk of distant metastasis or death at three years.
Pancreatic trial (n=16): ~90% of immune responders alive 4–6 years after surgery vs ~25% of non-responders — hypothesis-generating, not proof.
The reality check: BioNTech/Genentech halted a colorectal Phase 2 after MORE deaths in the vaccine-alone arm — same technology, different cancer, opposite result.
The Phase 3 result is a top-line press release, not yet peer-reviewed; the vaccine is not FDA-approved and is only available in clinical trials today.
Muscle, blood sugar control, sleep, not smoking, and sun protection remain the most proven cancer-risk tools you own right now.

Studies & sources:

Dr. Lufkin's book Lies I Taught in Medical School — more at robertlufkinmd.com and the Health Longevity Brief on Substack.

⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

Web: https://www.robertlufkinmd.com
YouTube: https://www.youtube.com/robertlufkinmd
X: https://x.com/robertlufkinmd
Instagram: https://www.instagram.com/robertlufkinmd/
TikTok: https://www.tiktok.com/@robertlufkin
LinkedIn: https://www.linkedin.com/in/robertlufkinmd/

The Breakthrough And The Big Question

SPEAKER_00 0:00

Last month, for the first time in history, a cancer vaccine passed a phase three clinical trial. Not a vaccine that prevents cancer, a vaccine custom built from a patient's own tumor designed to teach their immune system to hunt down the cancer cells that surgery left behind. Now, the company's stock jumped as much as 160% in a single day. So the question everyone is asking, will mRNA vaccines actually cure cancer? I'm Dr. Robert Lufkin, and we're today we're talking about mRNA cancer vaccines. What just happened, how they really work, and the honest answer to that question.

Phase Three Melanoma Trial Results

SPEAKER_00 0:43

Part one, what just happened? On August 19th, 2026, Moderna and Merck announced that their personalized mRNA vaccine called Intismeran Autogene succeeded in a phase three trial of more than 1,100 patients with high-risk melanoma that had been surgically removed. Patients who got the vaccine, plus the immunotherapy drug keytruda, stayed cancer-free longer than patients on ketruda alone. And the cancer was less likely to spread to distant organs. That has never happened before. This is literally the first mRNA cancer vaccine ever to succeed in a late-stage trial. And the first therapy of any kind shown to beat ketruda alone in this particular setting. One oncologist told ABC News that he expects FDA approval and patient availability possibly by early 2027.

How A Personalized mRNA Vaccine Works

SPEAKER_00 1:44

Part two. Every single dose is custom manufactured for one patient and no one else on Earth. It works like this. Surgeons remove your tumor. Scientists then sequence its DNA and compare it to your healthy DNA, hunting for the mutations unique to your cancer. Computer algorithms then pick up up to 34 of the most immune visible mutant proteins called neoantigens. And then these are encoded into a strand of mRNA. That's your vaccine. Think of it as a most wanted poster for your immune system. The mRNA teaches your cells to display those mutant proteins. Your T cells memorize the phases and then they patrol your body, hunting down any surviving cancer cell that wears them. And notice what made this possible.

Evidence Strength And Early Pancreatic Data

SPEAKER_00 3:22

So, how strong really is the evidence? The phase three results are top line for now, but the earlier phase 2B trial just published its five-year follow-up and the effect held. Adding the vaccine to Keytruda cut the risk of melanoma recurrence or death by 49% over five years. In the three-year analysis, it also cut the risk of distant metastases or death by 62%. And melanoma may just be the beginning. BioNTech is testing a personalized mRNA vaccine in pancreatic cancers, one of the deadliest cancers we know, with a five-year survival rate around 13%. In a small first inhuman trial at Memorial Sloan Kettering, the vaccine activated tumor-specific T cells in about half of 16 patients. Among those responders, nearly 90% were still alive four to six years after surgery. Among the non-responders, rather, only 25% survived. But stay tuned. We're going to have some late breaking news on that later. Read that again. In pancreatic cancer, the patients whose immune systems learned the lesson mostly lived. Those whose immune systems didn't mostly died. That's a signal you can't ignore even in 16 patients.

What “Cure” Means After Surgery

SPEAKER_00 4:44

Part four. So will they cure cancer? Now, the honest answer to the title question. These are not prevention vaccines. In other words, you can't line up for a shot that stops cancer before it starts. And they're not yet treatments for advanced widespread disease. Where they shine is a very specific window. After surgery removes the visible tumor, the vaccine trains your immune system to eliminate the invisible cells left behind, the ones that cause relapse. That reframes what a cure even means, because most cancer deaths don't come from the first tumor. They come from the recurrence, you know, the metastases, the second act. A therapy that teaches your body to police itself against your own specific cancer, potentially for years, attacks the second act directly. And the deeper story is the platform. Once you can sequence a tumor and print a bespoke vaccine in weeks, the same playbook extends to lung cancer, kidney cancer, pancreatic cancer, maybe even prostate cancer. Trials and all these are already running. This is medicine shifting from mass-produced drugs to individually manufactured ones. Arguably the biggest change in how we make medicines in a century.

Risks, Limits, And A Reality Check

SPEAKER_00 6:09

Part 5. But let's keep our feet on the ground. The phase three data is a company press release. Top line numbers, not yet peer-reviewed, and the detailed results haven't been published. The five-year data comes from a phase 2B trial of about 150 patients with confidence intervals that are still fairly wide. The pancreatic study was just 16 people, which is really hypothesis generating, but not proof. And the field just delivered its own reality check. Nine days after the melanoma trial, BioNTech and Genentech shut down a phase two trial of that same pancreatic vaccine, this time in colorectal cancer. Given alone, without an immunotherapy partner, the vaccine arm had more deaths than patients under simple observation. And an independent safety board stopped the study. The likely reason in immune cold tumors that suppress immune attack, the vaccine by itself may not be enough and may not even be harmless. Same technology, different cancer, opposite results. That's why we run the clinical trials. The vaccine is also not FDA approved, and manufacturing a unique drug for every patient is slow and expensive. Nobody knows yet what it will cost or who will get access. And this progress is happening while public funding for mRNA research is being cut in the United States, which could slow everything I just described. This is not medical advice, and if you're a cancer patient, these vaccines are available only inside clinical trials today. Part six, the takeaway.

Takeaway Plus Proven Risk Reducers

SPEAKER_00 8:00

Here's the takeaway. Well, will mRNA vaccines cure cancer? It's probably the wrong question. The right question is can we teach the immune system to finish the job surgery starts? And for the first time, a phase three trial says yes in melanoma and with more cancers in the pipeline. And remember what still sits upstream. Metabolic help shapes your the terrain your immune system fights on. Muscle, blood sugar control, sleep, not smoking, protecting your skin. These remain the most proven cancer risk tools you can own today.

Where To Get The Full Breakdown

SPEAKER_00 8:43

Now we're doing the full breakdown on the health longevity secrets podcast, link below. I'm Dr. Robert Lufkin, and we'll see you next week.